CLOs on the Move


 
At iA, we partner with our customers to transform pharmacy by deepening the patient-pharmacist relationship, enhancing patient safety and increasing operational efficiency.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.iarx.com
  • 711, Innovation Way
    Johnson City, NY USA 13790
  • Phone: 607.798.9376

Executives

Name Title Contact Details
Jessica Baer
General Counsel, Chief Legal Officer and Corporate Secretary Profile

Similar Companies

Mixlab

Mixlab is a modern veterinary pharmacy that specializes in pharmaceutical manufacturing and compounding for veterinary use.

Vein360

Vein 360 Specializes in reprocessing Closurefast Ablation Catheters. The Vein 360 team is dedicated to providing cost effective reprocessing services.

Servier Pharmaceuticals

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients` lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.